"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 28 | 9 | 37 |
| 1995 | 27 | 11 | 38 |
| 1996 | 33 | 21 | 54 |
| 1997 | 20 | 23 | 43 |
| 1998 | 45 | 20 | 65 |
| 1999 | 33 | 15 | 48 |
| 2000 | 37 | 24 | 61 |
| 2001 | 40 | 29 | 69 |
| 2002 | 61 | 30 | 91 |
| 2003 | 54 | 40 | 94 |
| 2004 | 65 | 43 | 108 |
| 2005 | 37 | 41 | 78 |
| 2006 | 28 | 11 | 39 |
| 2007 | 13 | 11 | 24 |
| 2008 | 17 | 16 | 33 |
| 2009 | 19 | 16 | 35 |
| 2010 | 19 | 16 | 35 |
| 2011 | 32 | 23 | 55 |
| 2012 | 22 | 21 | 43 |
| 2013 | 31 | 24 | 55 |
| 2014 | 32 | 22 | 54 |
| 2015 | 25 | 19 | 44 |
| 2016 | 20 | 6 | 26 |
| 2017 | 23 | 9 | 32 |
| 2018 | 10 | 6 | 16 |
| 2019 | 11 | 9 | 20 |
| 2020 | 15 | 11 | 26 |
| 2021 | 17 | 8 | 25 |
| 2022 | 2 | 11 | 13 |
| 2023 | 1 | 12 | 13 |
| 2024 | 6 | 11 | 17 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024 Oct 29; 15(1):9341.
-
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk. Cancer Discov. 2024 Oct 04; 14(10):1838-1859.
-
Can Ruxolitinib Crash TET2- and IDH2-Driven Clonal Hematopoiesis? Cancer Discov. 2024 Oct 04; 14(10):1768-1770.
-
ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica. 2024 Oct 01; 109(10):3419-3425.
-
Role of HIF-1a-Activated IL-22/IL-22R1/Bmi1 Signaling Modulates the Self-Renewal of Cardiac Stem Cells in Acute Myocardial Ischemia. Stem Cell Rev Rep. 2024 Nov; 20(8):2194-2214.
-
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia. 2024 Oct; 38(10):2073-2084.
-
Synergistic activation by Glass and Pointed promotes neuronal identity in the Drosophila eye disc. Nat Commun. 2024 Aug 17; 15(1):7091.
-
Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prev Res (Phila). 2024 Jul 02; 17(7):335-342.
-
Atrial Fibrillation and Clonal Hematopoiesis in TET2 and ASXL1. JAMA Cardiol. 2024 Jun 01; 9(6):497-506.
-
Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives. Future Oncol. 2024; 20(20):1435-1450.